
    
      We hypothesize that there are changes in circulating A-FABP level which can be mitigated by
      effective treatment of OSA.

      The aim is to investigate the effect of CPAP treatment of OSA on circulating A-FABP, and
      other metabolic biomarkers and cardiovascular parameters
    
  